AstraZeneca (AZN)
(Delayed Data from NSDQ)
$68.53 USD
+0.27 (0.39%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $68.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
AZN 68.53 +0.27(0.39%)
Will AZN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Other News for AZN
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
UK earnings, trading statements calendar - next 21 days
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
AstraZeneca upgraded to Hold from Sell at Deutsche Bank (earlier)
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials